entertainment -WSS

entertainment

author：comprehensive 2025-10-01 17:19:44 - browse：48818

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： In age of alternative facts, a scholarly course on calling out crap

leisure time

WSS

Hospital chaplains balance Covid safety with patients’ spiritual needs

Duchenne breakthrough therapy leaves behind pioneering families

Trump demands the U.S. pay no more for drugs than other countries … again

Boston Scientific acquires urology company Axonics for $3.7 billion

Sports medicine is finally prioritizing gender equality

Boston Scientific acquires urology company Axonics for $3.7 billion

explore

entertainment

focus

Anesthesiologist group: stop taking Ozempic before surgery

Activists slam private health insurers over coverage restrictions

As demand for Covid shots wanes, Moderna seeks its next success

Sports medicine is finally prioritizing gender equality

Continuity nursing helped my family in our darkest PICU moments

Medicare proposal to cover medical devices draws a mixed reaction

In Memoriam: Notable people who died in 2023

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Dobbs anniversary: the lost opportunity of abortion as health care

Arena BioWorks launches in Cambridge to speed drug discovery

hotspot

The high cost of giving birth even with insurance

Life science postdocs should get big pay hike, NIH panel says

State Dept. review finds Biden bears some blame for Afghanistan failures

Jerome Adams on the need for new antivirals for Covid

Walensky prepares to leave CDC — and Congress — behind

Walensky prepares to leave CDC — and Congress — behind

Wikipedia

leisure time

leisure time

leisure time